prikaz prve stranice dokumenta High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity
Rad je dostupan svim korisnicima iz sustava znanosti i visokog obrazovanja RH
Znanstveni rad - Izvorni znanstveni rad
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity
International Journal of Hematology, 112 (2020), 2; 141-146. https://doi.org/10.1007/s12185-020-02920-y
Caocci, Giovanni; Vignetti, Marco; Patriarca, Andrea; Breccia, Massimo; Platzbecker, Uwe; Palumbo, Giuseppe A.; Stauder, Reinhard; Cottone, Francesco; Petranović, Duška; Voso, Maria Teresa; Tafuri, Agostino; Invernizzi, Rosangela; Caers, Jo; Luppi, Mario; La Nasa, Giorgio; Niscola, Pasquale; Efficace, Fabio Više autora...

Citirajte ovaj rad

Caocci, G., Vignetti, M., Patriarca, A., Breccia, M., Platzbecker, U., Palumbo, G. A. ... Efficace, F. (2020). High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. International Journal of Hematology, 112. (2), 141-146. doi: 10.1007/s12185-020-02920-y

Caocci, Giovanni, et al. "High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity." International Journal of Hematology, vol. 112, br. 2, 2020, str. 141-146. https://doi.org/10.1007/s12185-020-02920-y

Caocci, Giovanni, Marco Vignetti, Andrea Patriarca, Massimo Breccia, Uwe Platzbecker, Giuseppe A. Palumbo, Reinhard Stauder, et al. "High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity." International Journal of Hematology 112, br. 2 (2020): 141-146. https://doi.org/10.1007/s12185-020-02920-y

Caocci, G., et al. (2020) 'High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity', International Journal of Hematology, 112(2), str. 141-146. doi: 10.1007/s12185-020-02920-y

Caocci G, Vignetti M, Patriarca A, Breccia M, Platzbecker U, Palumbo GA, i sur.. High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. International Journal of Hematology [Internet]. 2020. [pristupljeno 11.11.2024.];112(2):141-146. doi: 10.1007/s12185-020-02920-y

G. Caocci, et al., "High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity", International Journal of Hematology, vol. 112, br. 2, str. 141-146, 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:372655. [Citirano: 11.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:372655
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity
AutorGiovanni Caocci
AutorMarco Vignetti
AutorAndrea Patriarca
AutorMassimo Breccia
AutorUwe Platzbecker
AutorGiuseppe A. Palumbo
AutorReinhard Stauder
AutorFrancesco Cottone
AutorDuška Petranović
AutorMaria Teresa Voso
AutorAgostino Tafuri
AutorRosangela Invernizzi
AutorJo Caers
AutorMario Luppi
AutorGiorgio La Nasa
AutorPasquale Niscola
AutorFabio Efficace
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
We examined the association between serum ferritin (SF) levels and patient-reported functional aspects and symptoms, as measured by the EORTC QLQ-C30, in newly diagnosed patients with myelodysplastic syndromes (MDS). Analysis was conducted on 497 MDS patients who were classified in two groups based on the SF value of 1000 ng/mL. Clinically relevant differences of patient-reported functional and symptom scales were evaluated and classified as small, medium and large, based on established thresholds. Multivariable linear regression analysis was performed to account for potential confounding factors. Patients with SF of ≥ 1000 ng/mL reported statistically significant and clinically relevant worse outcomes across various health domains. Dyspnea was the symptom indicating the largest difference and mean scores of patients with higher and lower SF levels were 40 and 24.3, respectively (p = 0.005), indicating a large clinically relevant difference (Δ = 15.7). Further research is needed to better understand the relationship between SF levels and specific health-related quality of life domains.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaInternational Journal of Hematology
Brojčani podacivol. 112, br. 2, str. 141-146
p-ISSN0925-5710
DOIhttps://doi.org/10.1007/s12185-020-02920-y
URN:NBNurn:nbn:hr:184:372655
Datum objave publikacije2020
URL dokumentahttp://bib.irb.hr/1107118
Vrsta resursaTekst
Prava pristupaOgraničen pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-02-22 07:30:04